XML 46 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Revenue Recognition - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Pfizer Incorporation
Nonsoftware License Arrangement
Sep. 30, 2013
Pfizer Incorporation
Nonsoftware License Arrangement
Sep. 30, 2013
Pfizer Incorporation
Nonsoftware License Arrangement
Dec. 31, 2012
Pfizer Incorporation
Nonsoftware License Arrangement
Jan. 31, 2013
Pfizer Incorporation
Nonsoftware License Arrangement
Up-front Payment Arrangement
Sep. 30, 2013
Orencia Royalties from Bristol
Sep. 30, 2012
Orencia Royalties from Bristol
Sep. 30, 2013
Orencia Royalties from Bristol
Sep. 30, 2012
Orencia Royalties from Bristol
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]                          
Royalty revenue $ 6,637,838 $ 3,981,059 $ 15,654,919 $ 11,327,500           $ 4,825,000 $ 3,963,000 $ 12,956,000 $ 10,623,000
Percentage of royalty revenue, remittance to the University of Michigan     15.00%                    
Cost of royalty and other revenue 723,777 594,406 1,943,370 1,593,427           724,000 594,000 1,943,000 1,593,000
Payment received under license agreement                 5,000,000        
Milestone Payment         1,000,000                
Total future milestone receivable         64,000,000 64,000,000 64,000,000            
License agreement, revenue recognized           1,093,000 1,217,000 4,876,000          
Revenue from sponsored research and development projects $ 719,000 $ 18,000 $ 1,481,000 $ 704,000